Drug profile

The FDA adverse-event record for Ketoconazole, Trizedta

11 FDA reports name Ketoconazole, Trizedta, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2472 of 2,679
by report volume (all drugs)
11
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Ketoconazole, Trizedta ranks #2412 of 2679 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2412
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Signature read: 11 reports place Ketoconazole, Trizedta in the lower third of FDA AER volume (#2472 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
0
Deaths Reported
0.0%
Death-coded share of reports

Active Ingredients

Ketoconazole, Trizedta

Administration Routes

Auricular (Otic)UnknownTopical

Species Affected

Dog 8
Cat 3

Most Affected Breeds

Spaniel - Springer (unspecified) 2
Domestic Shorthair 2
Chow Chow 2
Retriever - Golden 1
Catahoula Leopard Dog 1
Terrier - Bull - Staffordshire 1
Cat (unknown) 1
Spaniel - King Charles Cavalier 1

Most Reported Reactions

Lack of efficacy - NOS 3
Limb weakness 3
Ataxia 3
Weight loss 3
Decreased appetite 3
Loss of hearing 2
Head bobbing 2
Otitis externa 2
Epiphora 2
Reluctant to move 2
Ear irritation 2
Medication error NOS 2

Outcome Breakdown

Ongoing
7 (63.6%)
Recovered/Normal
2 (18.2%)
Recovered with Sequela
1 (9.1%)
Outcome Unknown
1 (9.1%)

Ketoconazole, Trizedta: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Next steps with this data

  • Before drawing conclusions from this number, read why death-coded share is not the same thing as a mortality rate. Understanding adverse events
  • The full drug directory has report counts for every product we track. All drugs

Correlation in adverse-event counts is not causation; consult a veterinarian before making a decision from this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Ketoconazole, Trizedta (#2472 of 2,679 by report volume); death-coded 0.0%. PlainBreed drug row · report volume stamp 11 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →